Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| I. Bokerias Sakhelobis … | Healthcare Services | 10.7% | 54th pct | 268 |
| G Da G | Healthcare Services | 9.8% | 50th pct | 268 |
| Arensia Eksploratori Me… | Healthcare Services | 8.5% | 46th pct | 268 |
| Katastropis Meditsinis … | Healthcare Services | 6.4% | 39th pct | 268 |
| Vorldvaid Klinikal Trai… | Healthcare Services | 4.7% | 34th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | I. Bokerias Sakhelobis … | Arensia Eksploratori Me… | Katastropis Meditsinis … | Vorldvaid Klinikal Trai… | G Da G |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 97.6% | 49.8% | 33.2% | 32.7% | 67.0% |
| EBITDA Margin | 10.7% | 8.5% | 6.4% | 4.7% | 9.8% |
| EBITDAR | 1,354 | 1,012 | 565 | 793 | 756 |
| EBITDAR Margin | 14.0% | 13.2% | 8.7% | 12.4% | 12.0% |
| EBIT Margin | 8.8% | 7.6% | -0.8% | 2.9% | 9.0% |
| Net Profit Margin | 5.8% | 6.2% | 5.4% | 1.5% | 7.7% |
| Operating Expense % of Sales | 86.9% | 41.4% | 26.9% | 28.0% | 57.2% |
| Returns | |||||
| Return on Assets (ROA) | 18.2% | 22.8% | 5.3% | 9.6% | 31.1% |
| Return on Equity (ROE) | 18.5% | 24.3% | 12.5% | N/A | 266.3% |
| ROIC [EBIT / Invested Capital] | 42.6% | 33.1% | |||
| -1.3% |
| N/A |
| 57.6% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | 20.6% | 0.0% | 54.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.49x | -0.00x | 4.62x |
| Debt-to-EBITDA | 0.00x | 0.00x | 3.33x | 0.00x | 1.36x |
| Equity-to-Assets | 98.2% | 93.9% | 42.3% | -43.4% | 11.7% |
| Net Debt | -1,020 | -184 | 1,189 | -203 | 804 |
| Cash & Equivalents | 1,020 | 184 | 187 | 203 | 36 |
| Total Debt | N/A | N/A | 1,376 | N/A | 839 |
| Liquidity & working capital | |||||
| Current Ratio | 48.55x | 15.05x | 1.55x | 0.29x | 1.70x |
| Quick Ratio | 48.55x | 15.05x | 1.55x | 0.29x | 1.70x |
| Cash Ratio | 43.11x | 1.44x | 0.06x | 0.14x | 0.04x |
| Total Current Assets | 1,149 | 1,925 | 4,705 | 415 | 1,495 |
| Total Current Liabilities | 24 | 128 | 3,043 | 1,438 | 877 |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Trade Receivables | N/A | 1,705 | 3,817 | 155 | 31 |
| Trade Payables | 24 | 128 | 2,245 | 40 | 401 |
| Net Working Capital | 1,125 | 1,797 | 1,662 | -1,023 | 618 |
| Net Working Capital % of Revenue | 11.6% | 23.4% | 25.6% | -16.0% | 9.8% |
| Trade Working Capital | -24 | 1,577 | 1,572 | 115 | -371 |
| Trade Working Capital % of Revenue | -0.2% | 20.6% | 24.2% | 1.8% | -5.9% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | N/A | 4.50x | 1.70x | 41.16x | 202.98x |
| Days Sales Outstanding (DSO) | N/A | 81.1 | 214.9 | 8.9 | 1.8 |
| Payables Turnover | 9.93x | 30.09x | 1.93x | 106.38x | 5.17x |
| Days Payable Outstanding (DPO) | 36.7 | 12.1 | 189.3 | 3.4 | 70.6 |
| Cash Conversion Cycle | -36.7 days | 69.0 days | 25.6 days | 5.4 days | -68.8 days |
| Asset Turnover | 3.14x | 3.68x | 0.97x | 6.38x | 4.04x |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | N/A | 726 | 205 | 12,442 |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | 126 | 55 | -51 |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | 175.8% | 68.9% | 2021.6% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |